Circulation. 2008;118:1605-1606
doi: 10.1161/CIRCULATIONAHA.108.191122
(Circulation. 2008;118:1605-1606.)
© 2008 American Heart Association, Inc.
Clinical Summaries
An extract of the first 250 words of the full text is provided, because this article has no abstract.
|
 |
Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival
|
|---|
Atrial fibrillation (AF) is the most common arrhythmia in the
general population and a frequent postoperative complication
of cardiac surgery. AF is now widely recognized as a risk factor
for stroke and other thromboembolic complications and heart
failure. This leads to a substantial disease burden and significant
medical costs. Although many studies have examined the impact
of AF on the perioperative period, none has managed to present
compelling data that support an independent association between
postoperative AF and late mortality. Despite attempts to account
for confounding, it remains a distinct possibility that AF is
as associated with mortality as with potentially fatal comorbidities.
Previously published studies have not provided plausible direct
mechanisms that link postoperative AF with late mortality. In
addition, the causes of death have not been investigated. In
this study, we aimed to ascertain the impact of AF after coronary
surgery on postoperative survival, assessing its prognostic
role on cause-specific mortality. Our data have given perspective
on the possible role of AF among these patients and the effect
of embolic events in causing mortality. See p 1612.
 |
Milrinone Use Is Associated With Postoperative Atrial Fibrillation After Cardiac Surgery
|
|---|
Approximately 500 000 patients undergo cardiac surgery in the
United States each year. Postoperative atrial fibrillation is
a common complication after surgery that causes morbidity and
prolongs hospitalization. Milrinone use on the day of surgery
was associated with an increased risk of postoperative atrial
fibrillation even after controlling for other risk factors such
as age, ejection fraction, and increased pulmonary artery pressure.
These findings have clinical and financial implications. Milrinone
. . . [Full Text of this Article]